Home
overview

SMi Group announces the 22nd Annual Superbugs & Superdrugs Conference in London on March 16th - 17th 2020.


As one of the most impactful pharmaceuticals for maintaining public health, antibiotics have been around since early 20th century and have since shown a need for significant progress in recent years. This is mainly due to its broad and indiscriminate use which has slowly given birth to multi- to extensively-drug resistant bacteria rendering our current last-resort antibiotic arsenal, including colistin, carbapenems, 3rd and 4th generation cephalosporins, useless.


This year’s event aims to showcase a suite of sessions focused on novel drugs and approaches, particularly highlighting non-traditional and traditional therapies that provide an innovative means to spearhead the issue. The conference will also place significant emphasis on the much-needed support for innovative approaches such as sessions tackling the funding and support and the regulation that provides guidance towards the goal of ameliorating the continued rise of anti-microbial resistance AMR.


It is crucial to bring industry leaders together to discuss the strategies in place that reduce AMR, evaluate the role pharmaceutical companies and funding bodies play in reducing AMR, learn about new diagnostics approaches to identify AMR and consider novel candidates and alternatives to anti-microbials. Join us in March 2020, along with leaders from the pharmaceutical industry, academia, regulatory and funding bodies, and public-private partnerships to discuss the way forward.
 

ACS Dobfar SpA; Aelin Therapeutics; Akthelia Pharmaceuticals; AMR Centre; Bioharmony Therapeutics; BioVersys AG; Blueberry Therapeutics Ltd; Case Western Reserve University; Centauri Therapeutics; Charles River; Chemical Biology Ventures; Destiny Pharma; Drug Discovery Today; Evotec (UK) Ltd; Evotec UK Ltd; F2G Ltd; Fairy Gut Mother; Genentech; GSK; Helperby; HPRA; King Abdulaziz University; LifeArc; Meiji Seika Pharma Co. Ltd.; Meiji Seika Pharma Co., Ltd.; Morton Findlay Associates Ltd; MycoBiologics at University of Aberdeen; Nektr Technologies; Oxford University; Phico Therapeutics; PSI CRO AG; Russell Publishing Ltd; SCYNEXIS Inc; Therapeutics; TranScrip Partners; University of Birmingham; University Of Liverpool; University of North Texas Health Science Center; Walter Reed Army Institute of Research; Wellcome Trust; WHO; Wollongong Hospital;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Cara Cassino

Cara Cassino, Chief Medical Officer, ContraFect
View Bio

9:10 Exploring new classes of non-antibiotic antibacterial proteins: Colicins and Colicin-like Bacteriocins

Yuri Gleba

Yuri Gleba, CEO, Nomad Bioscience GMBH
View Bio

• Origins of non-antibiotic antibacterial proteins – a brief history
• A brief summary of the efficacy and potency of bacteriocins
• Methods and approach to bacteriocin expression – plant hosts
• Key commercialisation aspects, challenges and product candidates
 

9:50 Neutralising bacterial virulence effectors: a new paradigm in fighting severe and resistant infections

Samareh Lajaunias

Samareh Lajaunias, Director, Combioxin SA

• Neutralising virulence effectors
• CAL02: agent chemistry and activity
• Showcasing the results of CAL02 randomised, double-blind, multicentre, placebo-controlled trial
• Exploring the current regulatory landscape around neutralisation of virulence factors and beyond
 

10:30 Morning Coffee

11:00 Exploring Direct Lytic Agents (DLAs) and their potential as a successful disruptive anti-infective technology

Cara Cassino

Cara Cassino, Chief Medical Officer, ContraFect
View Bio

• Analysing the characteristics and benefits of DLAs against drug-resistant pathogens
• A look at the broad-based Gram-negative discovery program that optimises and develops DLA targets
• Explore the Exebacase performance as the only lysin to enter human clinical trials in the US entering phase 3
• Gain insight into the progress of the pipeline: GN Lysins and Amurins
• Evaluating the future outlook of DLA therapeutics
 

11:40 Boosting the antibiotic pipeline through the expansion of portfolio partnerships

Mark Albrecht

Mark Albrecht, Project Officer, HHS/ASPR/BARDA
View Bio

• An outline of the current and prospective antibiotic R&D partnerships
• Hear about BARDA’s contribution to combat antibiotic resistant infections in the US
• Gain insight into biopharmaceutical incubators that facilitate meeting objectives
• Establishing a biopharmaceutical incubator to meet short- and long-term goals
• Explore BARDA funding opportunities
 

12:20 Networking Lunch

13:20 Candida auris: rise of a superbug

Stephen Barat

Stephen Barat, Vice President, Preclinical Research and Early Development, Scynexis
View Bio

• Background, epidemiology and global spread
• Why Candida auris presents a significant cause for concern
• The concern for AMR and the potential utility of new antifungals such as Ibrexafungerp
 

14:00 Immunomodulatory Therapies

Pedro Madureira

Pedro Madureira, CSO, Immunethep
View Bio

• Extracellular Bacterial GAPDH
• Common Virulence Mechanism
• Restore Immune system ability to control infection
 

14:40 Afternoon Tea

15:10 Panel Discussion: The development of non-traditional therapies in ID: known and unknown hurdles

Antonio Perez

Antonio Perez, Chief Medical Officer, Senior Subject Matter Expert, Combioxin SA
View Bio

• What are non-traditional therapies?
• Could efficacy assessments (non-clinical and clinical) used for antibiotics apply to non-traditional agents?
• Are there alternatives to antibiotics or to be administered in combination with antibiotics?
• What are the regulatory guidelines for the development of non-traditional therapies?
• What is the place of non-traditional therapies in terms of financial support and regulatory designations?
• How do non-traditional therapies address the resistance threat?
 

16:10 Chair’s Closing Remarks and Close of Day One

Cara Cassino

Cara Cassino, Chief Medical Officer, ContraFect
View Bio

8:30 Registration & Coffee

9:00 Chair's Opening Remarks

9:10 Update on the UK project looking at novel value assessment and reimbursement for novel antimicrobials

Colm Leonard

Colm Leonard, Consultant Clinical Adviser to NICE/Consultant Thoracic Physician & Honorary Professor of Medicine, Manchester Academic Health Sciences Centre, NICE
View Bio

• Background to UK project
• Components of UK project
• Progress to date and global context
 

9:50 Evaluating the utility of machine learning and AI in antibiotic drug discovery

Paul Finn

Paul Finn, CEO, Oxford Drug Design
View Bio

• Explore the applicability of machine learning and AI in accelerating antibiotic drug discovery and development
• The technology behind the machine: proprietary 3D ElectroShape technology and the Scopius compound database
• Case study: Aminoacyl tRNA (aaRS) Synthetase Inhibitors
• See the opportunities and challenges that face regulator and clinician acceptance
 

10:30 Morning Coffee

11:00 Discovery and progress of Metallo-ß-Lactamase inhibitor (MBLi) as a potent agent against NDM-carbapanem resistant CRE

Martin Everett

Martin Everett, Chief Scientific Officer , Antabio

• Worldwide CRE prevalence summary
• Discovery of a novel MBL-inhibitor: ANT431 and reinstating susceptibility
• Progress of the MBLi programme towards a preclinical candidate: ANT2681
• The future of antibiotic adjuvants and combination therapies
 

11:40 Discovery of Dabocins, a novel class of non-ß-lactam PBP inhibitors

Francois Moreau

Francois Moreau, Scientific Director, Mutabilis S A

• EBL-1463 is a DBO-based covalent inhibitor of Penicillin-Binding Proteins 1a, 2, 3
• It is stable to class A, B, C, D β-lactamases, direct-acting and bactericidal against Enterobacterales
• Overview of MIC profiles and in vivo efficacy against highly resistant MBL-producing CRE
• Early PK/PD and human dose prediction
 

12:20 Networking Lunch

13:20 Highly targeted protein antibiotics for the prevention and treatment of bacterial infections

Daniel Walker

Daniel Walker, Professor of Microbiology, University of Glasgow

• Protein antibiotics that show good in vivo efficacy against major Gram-negative pathogens have been identified
• Show extensive distribution into different organs when administered intravenously
• Selective targeting of pathogenic species can be achieved in the complex environment of the intestinal microbiota
 

14:00 Precision biofilm disruption and vaginome editing with phage-based technologies

Lorenzo Corsini

Lorenzo Corsini, Co-Founder, CEO, Research & Development, Phagomed Biopharma GmbH

• PhagoMed is an Austrian pre-clinical biotech company focused on developing treatments against persistent, biofilm-associated infections. We will present two of our key assets
• PM-398: PhagoMed’s cocktail of natural, propagating S. aureus phages could transform the standard of care in implant associated infections
• PM-477: PhagoMed’s recombinant, Gardnerella-specific endolysin precisely edits the vaginal microbiome and is being developed for the treatment of bacterial vaginosis
 

14:40 Afternoon Tea

15:10 Inhibition of bacterial cell-wall biosynthesis by carbohydrate scaffolds targeting the glycosyltransferase activity of penicillin-binding proteins

David Roper

David Roper, Professor of Biochemistry and Structural Biology, University of Warwick

• Penicillin binding proteins (PBPs) as excellent targets for antibacterials as exemplified by the mode of action of beta-lactams
• Class A PBPs are responsible for the polymerisation of the peptidoglycan precursor, Lipid II into a glycan polymer required for subsequent transpeptidation crosslinking reactions by all PBPs
• Development of a series of sugar base inhibitors of this process with promising in-vitro in-vivo properties of this Class A PBP polymerisation process
• Exploring the mode of action providing a novel perspective on targeting bacterial cell wall biosynthesis
 

16:00 Novel Immunotherapeutics to target Gram-negative bacterial infections

Emma Leire

Emma Leire, Microbiology Lead, Centauri Therapeutics Ltd

• Natural antibodies and the discovery of alpha-Gal
• Alphamer platform and how to harness the power of the immune system
• ABX01 mechanism of action in vitro and in vivo
• Translation of immune-recruiting agents in preclinical PK/PD
 

16:40 Chair’s Closing Remarks and Close of Day Two

+

Sponsors

VENUE

Holiday Inn Kensington Forum

97 Cromwell Road , London, United Kingdom

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
HOTEL BOOKING FORM

Sponsors


SCYNEXIS

Sponsors
http://www.scynexis.com

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, SCY-078, is a novel IV/oral antifungal agent in Phase 2 clinical and preclinical development for the treatment of several serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit www.scynexis.com.

SAVE TO


Outlook Calendar  OUTLOOK CALENDAR
Google Calendar  GOOGLE CALENDAR
ICal Calendar  ICAL CALENDAR
Yahoo! Calendar  YAHOO! CALENDAR

Holiday Inn Kensington Forum

97 Cromwell Road
London SW7 4DN
United Kingdom

Holiday Inn Kensington Forum

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SMi GROUP LTD

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71




Forgotten Password

Please enter the email address you registered with. We will email you a new password.

Thank you for visiting our event

If you would like to receive further information about our events, please fill out the information below.

By ticking above you are consenting to receive information by email from SMi.
Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out